Sandboxrx1: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (12 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{ | {|class="infobox" style="position: fixed; top: 180px; right: 20px; margin: 0 0 0 0; border: 0; float: right; width: 15%; background: #104E8B; border-radius: 10px 10px 10px 10px;" cellpadding="0" cellspacing="0"; | ||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #104E8B;" | [[{{PAGENAME}}|{{fontcolor|#F8F8FF|{{PAGENAME}}®}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #000000; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Black Box Warning|{{fontcolor|#FF0000|Black Box Warning}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Adult Indications and Dosage|{{fontcolor|#F8F8FF|Adult Indications and Dosage}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Pediatric Indications and Dosage|{{fontcolor|#F8F8FF|Pediatric Indications and Dosage}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Contraindications|{{fontcolor|#F8F8FF|Contraindications}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Warnings|{{fontcolor|#F8F8FF|Warnings}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Adverse Reactions|{{fontcolor|#F8F8FF|Adverse Reactions}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Drug Interactions|{{fontcolor|#F8F8FF|Drug Interactions}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Use in Specific Populations|{{fontcolor|#F8F8FF|Use in Specific Populations}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Administration and Monitoring|{{fontcolor|#F8F8FF|Administration and Monitoring}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#IV Compatibility|{{fontcolor|#F8F8FF|IV Compatibility}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Overdosage|{{fontcolor|#F8F8FF|Overdosage}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Pharmacology|{{fontcolor|#F8F8FF|Pharmacology}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Clinical Studies|{{fontcolor|#F8F8FF|Clinical Studies}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#How Supplied|{{fontcolor|#F8F8FF|How Supplied}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Images|{{fontcolor|#F8F8FF|Images}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Patient Information|{{fontcolor|#F8F8FF|Patient information}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Precautions with Alcohol|{{fontcolor|#F8F8FF|Precautions with Alcohol}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Brand Names|{{fontcolor|#F8F8FF|Brand Names}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [[{{PAGENAME}}#Look-Alike Drug Names|{{fontcolor|#F8F8FF|Look-Alike Drug Names}}]] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050792.htm {{fontcolor|#F8F8FF|Drug Shortage Status}}] | |||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #6D9CC9; border-radius: 5px 5px 5px 5px;" align=left | [http://www.goodrx.com/{{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}/price {{fontcolor|#F8F8FF|Price}}] | |||
|- | |||
|} | |||
<div style="width: 80%"> | <div style="width: 80%"> | ||
__NOTOC__ | __NOTOC__ | ||
| Line 5: | Line 51: | ||
'''''For information about (Generic Name), click [[(Generic Name)|here]].''''' | '''''For information about (Generic Name), click [[(Generic Name)|here]].''''' | ||
{{SB}} | |||
==Disclaimer== | ==Disclaimer== | ||
'''''WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature. The information provided is not a medical advice or treatment. WikiDoc does not promote any medication or off-label use of drugs. Please read our full disclaimer [[wikidoc:General_disclaimer|{{fontcolor|#FF0000|here}}]].''''' | |||
==<span style="color:#FF0000; background:#000000;">Black Box Warning</span>== | ==<span style="color:#FF0000; background:#000000;">Black Box Warning</span>== | ||
FDA Package Insert for {{PAGENAME}} contains no information regarding ''Black Box Warning''. | |||
{| style="border: 3px solid #696969;" | {| style="border: 3px solid #696969;" | ||
| Line 39: | Line 89: | ||
* Dosing Information | * Dosing Information | ||
: | :* (Dosage) | ||
=====Condition 2===== | =====Condition 2===== | ||
| Line 45: | Line 95: | ||
* Dosing Information | * Dosing Information | ||
: | :* (Dosage) | ||
===Off-Label Use and Dosage (Adult)=== | ===Off-Label Use and Dosage (Adult)=== | ||
| Line 59: | Line 109: | ||
* Strength of Evidence: (Category A/B/C) (Link) | * Strength of Evidence: (Category A/B/C) (Link) | ||
* Dosing Information | * Dosing Information/Recommendation | ||
: | :* (Dosage) | ||
=====Condition 2===== | =====Condition 2===== | ||
| Line 71: | Line 121: | ||
* Strength of Evidence: (Category A/B/C) (Link) | * Strength of Evidence: (Category A/B/C) (Link) | ||
* Dosing Information | * Dosing Information/Recommendation | ||
: | :* (Dosage) | ||
====Non–Guideline-Supported Use==== | ====Non–Guideline-Supported Use==== | ||
| Line 81: | Line 131: | ||
* Dosing Information | * Dosing Information | ||
: | :* There is limited information about ''Off-Label Non–Guideline-Supported Use'' of {{PAGENAME}} in adult patients. | ||
=====Condition 2===== | =====Condition 2===== | ||
| Line 87: | Line 137: | ||
* Dosing Information | * Dosing Information | ||
: | :* (Dosage) | ||
=====Condition 3===== | =====Condition 3===== | ||
| Line 93: | Line 143: | ||
* Dosing Information | * Dosing Information | ||
: | :* (Dosage) | ||
==Pediatric Indications and Dosage== | ==Pediatric Indications and Dosage== | ||
| Line 103: | Line 153: | ||
* Dosing Information | * Dosing Information | ||
: | :* (Dosage) | ||
=====Condition 2===== | =====Condition 2===== | ||
| Line 109: | Line 159: | ||
* Dosing Information | * Dosing Information | ||
: | :* (Dosage) | ||
===Off-Label Use and Dosage (Pediatric)=== | ===Off-Label Use and Dosage (Pediatric)=== | ||
| Line 123: | Line 173: | ||
* Strength of Evidence: (Category A/B/C) (Link) | * Strength of Evidence: (Category A/B/C) (Link) | ||
* Dosing Information | * Dosing Information/Recommendation | ||
: | :* (Dosage) | ||
=====Condition 2===== | =====Condition 2===== | ||
| Line 135: | Line 185: | ||
* Strength of Evidence: (Category A/B/C) (Link) | * Strength of Evidence: (Category A/B/C) (Link) | ||
* Dosing Information | * Dosing Information/Recommendation | ||
: | :* (Dosage) | ||
====Non–Guideline-Supported Use==== | ====Non–Guideline-Supported Use==== | ||
| Line 145: | Line 195: | ||
* Dosing Information | * Dosing Information | ||
: | :* (Dosage) | ||
=====Condition 2===== | =====Condition 2===== | ||
| Line 151: | Line 201: | ||
* Dosing Information | * Dosing Information | ||
: | :* (Dosage) | ||
=====Condition 3===== | =====Condition 3===== | ||
| Line 157: | Line 207: | ||
* Dosing Information | * Dosing Information | ||
: | :* (Dosage) | ||
==Contraindications== | ==Contraindications== | ||
| Line 211: | Line 261: | ||
: (list/description of adverse reactions) | : (list/description of adverse reactions) | ||
=====Condition | =====Condition 2===== | ||
======Central Nervous System====== | ======Central Nervous System====== | ||
| Line 273: | Line 323: | ||
====Pregnancy==== | ====Pregnancy==== | ||
* '''[[Pregnancy category#United States|Pregnancy Category (FDA)]]: X''' | |||
* '''[[Pregnancy category#Australia|Pregnancy Category (AUS)]]: {{PAGENAME}} is not included in Australian Drug Evaluation Committee (ADEC) Pregnancy Categories.''' | |||
(Description) | (Description) | ||
| Line 311: | Line 361: | ||
(Description) | (Description) | ||
==== | ====Carcinogenesis, Mutagenesis, Impairment of Fertility==== | ||
(Description) | (Description) | ||
====Immunocompromised Patients==== | ====Immunocompromised Patients==== | ||
(Description) | |||
====Miscellaneous==== | |||
(Description) | (Description) | ||
| Line 596: | Line 650: | ||
===Drug Images=== | ===Drug Images=== | ||
( | {| | ||
| [[File:PILLIMAGE.jpg|thumb|300px|<p style="text-align: left;"> | |||
'''Drug Name''': <BR> | |||
'''Ingredient(s)''': <BR> | |||
'''Imprint''': <BR> | |||
'''Color(s)''': <BR> | |||
'''Shape''': <BR> | |||
'''Size (mm)''': <BR> | |||
'''Score''': <BR> | |||
'''Drug Label Author''': ]]</p> | |||
|} | |||
===Package and Label Display Panel=== | ===Package and Label Display Panel=== | ||
| Line 617: | Line 681: | ||
Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | ||
==Brand Names== | |||
Brand Names® | |||
==Look-Alike Drug Names== | ==Look-Alike Drug Names== | ||
Latest revision as of 21:49, 30 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For information about (Generic Name), click here.
Synonyms / Brand Names:
Disclaimer
WikiDoc Drug Project is a constellation of drug information for healthcare providers and patients vigorously vetted on the basis of FDA package insert, MedlinePlus, Practice Guidelines, Scientific Statements, and scholarly medical literature. The information provided is not a medical advice or treatment. WikiDoc does not promote any medication or off-label use of drugs. Please read our full disclaimer here.
Black Box Warning
FDA Package Insert for Sandboxrx1 contains no information regarding Black Box Warning.
|
WARNING See full prescribing information for complete boxed warning. Condition Name: (Content) |
Overview
Sandboxrx1 is a _______ drug that is FDA approved for the treatment of _______. There is a Black Box Warning for this drug as shown here. Common adverse reactions include _______.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition 1
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Condition 2
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Condition 1
- Dosing Information
- There is limited information about Off-Label Non–Guideline-Supported Use of Sandboxrx1 in adult patients.
Condition 2
- Dosing Information
- (Dosage)
Condition 3
- Dosing Information
- (Dosage)
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition 1
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Condition 2
- Developed by: (Organisation)
- Class of Recommendation: (Class) (Link)
- Strength of Evidence: (Category A/B/C) (Link)
- Dosing Information/Recommendation
- (Dosage)
Non–Guideline-Supported Use
Condition 1
- Dosing Information
- (Dosage)
Condition 2
- Dosing Information
- (Dosage)
Condition 3
- Dosing Information
- (Dosage)
Contraindications
- Condition 1
- Condition 2
- Condition 3
- Condition 4
- Condition 5
Warnings
Conidition 1
(Description)
Conidition 2
(Description)
Conidition 3
(Description)
Adverse Reactions
Clinical Trials Experience
Condition 1
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Condition 2
Central Nervous System
- (list/description of adverse reactions)
Cardiovascular
- (list/description of adverse reactions)
Respiratory
- (list/description of adverse reactions)
Gastrointestinal
- (list/description of adverse reactions)
Hypersensitive Reactions
- (list/description of adverse reactions)
Miscellaneous
- (list/description of adverse reactions)
Postmarketing Experience
(Description)
Drug Interactions
- Drug 1
- Drug 2
- Drug 3
- Drug 4
- Drug 5
Drug 1
(Description)
Drug 2
(Description)
Drug 3
(Description)
Drug 4
(Description)
Drug 5
(Description)
Use in Specific Populations
Pregnancy
- Pregnancy Category (AUS): Sandboxrx1 is not included in Australian Drug Evaluation Committee (ADEC) Pregnancy Categories.
(Description)
Labor and Delivery
(Description)
Nursing Mothers
(Description)
Pediatric Use
(Description)
Geriatric Use
(Description)
Gender
(Description)
Race
(Description)
Renal Impairment
(Description)
Hepatic Impairment
(Description)
Carcinogenesis, Mutagenesis, Impairment of Fertility
(Description)
Immunocompromised Patients
(Description)
Miscellaneous
(Description)
Administration and Monitoring
Administration
(Oral/Intravenous/etc)
Monitoring
Condition 1
(Description regarding monitoring, from Warnings section)
Condition 2
(Description regarding monitoring, from Warnings section)
Condition 3
(Description regarding monitoring, from Warnings section)
IV Compatibility
Solution
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Y-Site
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Admixture
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Syringe
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
TPN/TNA
Compatible
- Solution 1
- Solution 2
- Solution 3
Not Tested
- Solution 1
- Solution 2
- Solution 3
Variable
- Solution 1
- Solution 2
- Solution 3
Incompatible
- Solution 1
- Solution 2
- Solution 3
Overdosage
Acute Overdose
Signs and Symptoms
(Description)
Management
(Description)
Chronic Overdose
Signs and Symptoms
(Description)
Management
(Description)
Pharmacology
Sandboxrx1
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Mechanism of Action
(Description)
Structure
(Description with picture)
Pharmacodynamics
(Description)
Pharmacokinetics
(Description)
Nonclinical Toxicology
(Description)
Clinical Studies
Condition 1
(Description)
Condition 2
(Description)
Condition 3
(Description)
How Supplied
(Description)
- National Drug Code (NDC):
- Storage:
- Manufactured by:
- Distributed by:
Images
Drug Images
Drug Name: |
Package and Label Display Panel
(Package Images)
(Display Panel Images)
Patient Information
Patient Information from FDA
(Patient Counseling Information)
Patient Information from NLM
(Link to patient information page)
Precautions with Alcohol
Alcohol-Sandboxrx1 interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
Brand Names®
Look-Alike Drug Names
- (Paired Confused Name 1a) — (Paired Confused Name 1b)
- (Paired Confused Name 2a) — (Paired Confused Name 2b)
- (Paired Confused Name 3a) — (Paired Confused Name 3b)